www.uhasselt.be
DSpace

Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/8276

Title: Tovaxin, radiation-attenuated, patient-specific T-cells for the therapeutic vaccination of multiple sclerosis
Authors: HELLINGS, Niels
STINISSEN, Piet
Issue Date: 2008
Publisher: THOMSON SCIENTIFIC
Citation: CURRENT OPINION IN INVESTIGATIONAL DRUGS, 9(5). p. 534-540
Abstract: Opexa Pharmaceuticals Inc is developing Tovaxin, a trivalent formulation of attenuated myelin-peptide-reactive T-cells, for the potential treatment of multiple sclerosis. Tovaxin is being evaluated in phase II clinical trials. Opexa was previously investigating Tovaxin for the potential treatment of rheumatoid arthritis; however, no development has been reported for this indication since December 2002.
Notes: Hasselt Univ, Biomed Res Inst, B-3590 Diepenbeek, Belgium.
URI: http://hdl.handle.net/1942/8276
ISI #: 000255431300012
ISSN: 1472-4472
Category: A1
Type: Journal Contribution
Validation: ecoom, 2009
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
Preprint107.36 kBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.